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A B S T R A C T
Objective: To quantify the expression of human b-defensins (HBDs) 1, 3 and 4 in chorioamniotic
membranes in pregnancies complicated by prematurity associated with histologic chorioamnionitis.
Study design: The study group included 23 fragments of chorioamniotic membranes with histologic
chorioamnionitis from women with preterm premature rupture of membranes (PPROM) and preterm
labor (PTL) with intact membranes, who had preterm deliveries. As a control group, 30 chorioamniotic
membranes without chorioamnionitis at the same gestational age as those in the study group were
included. Chorioamniotic membranes were collected for histopathological analyses, and HBD mRNA
expression quantiﬁcation was analyzed by real time PCR. Comparisons were performed using the Mann–
Whitney or Kruskal–Wallis tests and all the women were informed and provided written consent.
Results: The expression of HBDs mRNA in the fetal membranes was similar in patients without histologic
chorioamnionitis (HBD1: 0.7-fold, HBD3: 0.9-fold, HBD4: 0.3-fold) compared to patients with
chorioamnionitis (HBD1: 1.1-fold, HBD3: 0.9-fold, HBD4: 0.4-fold; p > 0.05). Regarding the gestational
complications that resulted in premature delivery, PPROM or PTL, the relative quantiﬁcation of HBD1,
HBD3 and HBD4 showed no statistically signiﬁcant differences in either the absence or presence of
chorioamnionitis. Among patients with histologic chorioamnionitis, patients with PPROM (HBD1: 2.7-
fold, HBD3: 0.3-fold, HBD4: 0.7-fold) presented similar mRNA expression to those with PTL (HBD1: 0.7-
fold, HBD3: 1.2-fold, HBD4: 0.13-fold; p > 0.05).
Conclusions: Chorioamniotic membranes are sources of b defensins 1, 3 and 4; however, considering the
sample size and the methodology applied, mRNA concentrations were not related to the presence of
histologic chorioamnionitis.
 2011 Elsevier Ireland Ltd. 
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Chorioamniotic membranes compose a structure of great
importance for fetal development. Among its principal functions
are protection of the fetus from trauma, maintenance of amniotic
ﬂuid volume and protection of the umbilical cord and fetal blood
from compression, as well as serving as a barrier against lower
genital tract infections [1]. In addition to coating the placental
surface and forming the amniotic sac, fetal membranes act to
maintain ideal sterile conditions of the amniotic ﬂuid and are an
immunological barrier [1]. Recent studies have also suggested this
role for fetal membranes, demonstrating that this tissue expresses* Corresponding authors at: Department of Pathology, Botucatu Medical School,
Sa˜o Paulo State University, Distrito de Rubia˜o Ju´nior, CEP: 18618-970, Botucatu, Sa˜o
Paulo, Brazil. Tel.: +55 14 3811 6238; fax: +55 14 3815 2348.
E-mail address: mgsilva@fmb.unesp.br (M.G. Silva).
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Open access under the Elsevier OA license. antimicrobial agents [2] and components of the innate immune
system, such as Toll-like receptors [3,4].
The principal characteristic of innate immunity is its ability to
recognize a broad range of microorganisms, including Gram-
positive and -negative bacteria, fungi and viruses. In this context,
natural antimicrobials participate in the primary host defence
through the recognition and neutralization of invading micro-
organisms [5].
Small cationic antimicrobial peptides called human a-defen-
sins (or human neutrophil peptides, HNPs) and human b-defensins
(HBDs) have been described. HNPs 1–4 are present in azurophilic
granules in neutrophils and have an integral role in the oxygen-
independent extermination of bacteria [6], while HBDs constitute
the largest group of natural antimicrobials and are produced
primarily by epithelial cells [7]. There are 28 HBD sequences that
have already been detected in the human genome [8], but HBDs 1–
4 have been most extensively studied in the last decade [9]. The
ﬁrst, HBD1, was isolated from hemoﬁltrate [10] and, among other
tissues, is expressed in the genitourinary tract [11,12], respiratory
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HBD1 is well established in several tissues [14–16] and in these
cases, its expression is not affected by the production of
inﬂammatory mediators. Recent studies, however, show that this
natural antimicrobial can also be produced under microbial stimuli
[17–19]. With the particular advantage of forming dimers, the
expression of HBD3 has already been related to non-reproducing
tissues, such as those in the oral cavity [20], lungs [8] and bone
[21]. Recently, HBD3 was detected in myometrial and endometrial
tissue [22,23], with its highest expression in the early and late
secretory phase of the menstrual cycle. HBD4 was characterized
through the genome and, although already detected in endome-
trium [24] and other tissues, the highest HBD4 expression was
veriﬁed in the testis, followed by expression in the gastric antrum
[25]. In the uterus, neutrophils, thyroid glands, lungs and kidneys,
however, low HBD4 expression was veriﬁed and little is known
regarding the expression and regulation of this defensin in other
biological systems [25].
In the reproductive tract of nonpregnant women, natural
antimicrobials are present in the vagina, cervix, endometrium and
fallopian tubes [26,27]. In term pregnancies, antimicrobial agents
are present in the amniotic ﬂuid [28,29], chorion trophoblast layers
and amniotic epithelium of fetal membranes and placenta
[2,16,30,31]. This expression particularly by the fetal membranes
may be important during labor and delivery, when the cervix is
dilated, making the uterus more susceptible to infections. Amniotic
and chorionic cells obtained from term pregnancies were
described as having an inhibitory effect on the growth of many
bacterial species and this was suggested, in part, by the production
of endogenous antimicrobials by these tissues [32].
Histologic chorioamnionitis, deﬁned by the inﬁltration of fetal
membranes by polymorphonuclear leukocytes, occurs in most
cases in the absence of clinical signs and symptoms of infection and
this diagnosis can be made in more than 20% of term pregnancies
and in more than 50% of preterm births [33–35]. Recent studies
have determined a positive correlation between the presence of
neutrophil defensins in amniotic ﬂuid and maternal plasma in
preterm pregnancies, in the presence of infection of the amniotic
cavity [36,37]. Under inﬂammatory stimuli, HBD3 is the most
abundant and most highly expressed b-defensin in amniotic
epithelial cells [30]. Reports in the literature afﬁrm that in preterm
premature rupture of membranes (PPROM) and in clinical and
histologic chorioamnionitis, amniotic cells stimulated with lipo-
polysaccharide exhibit increased expression of HBD3 compared to
term pregnancies. Studies are still lacking, however, regarding the
activity and expression of HBDs in the chorioamniotic membranes
of preterm pregnancies and/or in the presence of infection of the
amniotic cavity [38].
Considering that inﬂammatory events in the amniotic cavity are
pronounced in pregnancies complicated by PPROM or preterm
labor (PTL) associated with histologic chorioamnionitis and that
chorioamniotic membranes have an inhibitory effect on the
growth of many bacteria, in part due to the production of b
defensins, the objective of this study was to quantify the
expression of HBDs 1, 3 and 4 by chorioamniotic membranes in
pregnancies complicated by prematurity associated with histolog-
ic chorioamnionitis.
2. Materials and methods
The study group consisted of women with singleton pregnan-
cies who presented with PPROM or PTL between 26 and 36 weeks
gestation and were admitted to the Obstetrics Unit of the Clinical
Hospital of Botucatu Medical School, State of Sa˜o Paulo, Brazil.
Gestational age was calculated from the ﬁrst day of the last
menstruation and/or from the ﬁrst trimester ultrasound. PROMwas diagnosed by sterile speculum examination conﬁrming
pooling of amniotic ﬂuid in the vagina, positive nitrazine paper
test, positive fern test and the search for fetal cells in
cervicovaginal secretion. PTL was deﬁned as the presence of
regular uterine contractions every 10 min or less and cervical
effacement equal or superior to 50% conﬁrmed by two observers
and/or cervical dilatation of at least 2 cm at less than 37 weeks of
gestation. PPROM and PTL were deﬁned according to the Brazilian
Ministry of Health guidelines, available at: (http://portal.saude.-
gov.br/portal/arquivos/pdf/Manual%20Puerperio%202006.pdf).
Exclusion criteria were multiple pregnancies, pre-eclampsia,
diabetes, fetal anomalies and placenta previa. No pregnant woman
included in this study presented with Chlamydia trachomatis
cervicitis or urinary tract infection during the pregnancy.
Chorioamnionitis was conﬁrmed in 23 chorioamniotic membranes
from the study group by histopathological evaluation. The control
group consisted of 30 chorioamniotic membranes from women
with singleton pregnancies without histopathologic chorioamnio-
nitis, with the same gestational age as the study group. In both
groups, all pregnant women had preterm delivery.
The Human Research Ethics Committee of the institution
approved the study (Protocol 3161-2009), and written informed
consent was obtained from all participants.
All the chorioamniotic membranes collected were stored in
RNA later1 (RNA Stabilization Reagent, Ambion) using 10 ml/mg
tissue at 80 8C. Samples of the membranes were ﬁxed in 10%
formalin, embedded in parafﬁn, sectioned and stained with
hematoxylin and eosin for histopathological analyses. Histologic
chorioamnionitis was diagnosed by the presence of neutrophilic
inﬁltration present in chorioamniotic membranes, according to
Yoon et al. [39].
Total RNA was extracted from chorioamniotic membrane
samples using Illustra RNAspin Mini Isolation kit (GE Healthcare).
To preclude genomic DNA contamination, all RNA samples were
treated with RNase-free DNAse I (New England Biolabs1) before
ampliﬁcation. The quality and concentration of extracted total RNA
were measured with a Nanodrop ND-1000 Spectrophotometer.
Sample RNA (0.1 mg/mL) was subjected to reverse transcription
using the High-Capacity cDNA Archive Kit, in accordance with the
manufacturer’s instructions (Applied Biosystems, Foster City, CA,
USA).
Real time quantitative PCR was used to quantify mRNA
expression of b defensins, and TaqMan-validated primers and
TaqMan MGB probes were used to amplify HBD1, HBD3 and HBD4
(ID Hs00174765_m1, Hs00218678_m1, and Hs00175474_m1,
respectively). Expression levels of the relevant genes in each
sample were normalized to TBP (TATA box binding protein, ID
Hs99999910_m1), which was used as the housekeeping gene.
Ampliﬁcation was performed using an ABI Prism1 7300 Sequence
Detector (Applied Biosystems), with an optical unit that permits
real-time monitoring of increased PCR product concentration. The
threshold cycle number (CT) is the PCR cycle number at which
ﬂuorescence release achieves a threshold level and was used to
determine relative HBD mRNA expression, using the ddCT method
[40]. The mean of CT from samples of patients without
chorioamnionitis was used as calibrator. Thermal cycling was
initiated with a denaturation step of 10 min at 95 8C followed by 40
cycles of 95 8C for 15 s and 60 8C for 1 min. All reactions were
performed in duplicate and no template controls were included in
each run.
Statistical analyses were performed with SigmaStat Software
version 3.1. After checking for normality of the data using the
Kolmogorov–Smirnov test (with Lilliefors’ correction), compar-
isons of each HBD mRNA concentration in relation to the presence
or absence of chorioamnonitis were performed using the
nonparametric Mann–Whitney test. For comparisons between
Fig. 1. Relative quantiﬁcation of human beta defensin (HBD) 1, 3 and 4 mRNA in
chorioamniotic membranes from pregnancies complicated or not by histologic
chorioamnionitis. Medians (horizontal lines) are shown. Mann–Whitney test
(p > 0.05).
Fig. 2. Relative quantiﬁcation of human beta defensin (HBD) 1, 3 and 4 mRNA in
chorioamniotic membranes from pregnancies complicated or not by histologic
chorioamnionitis. The squares represent cases with less than 32 week’s gestation,
and the circles represent cases with 32–36 full week’s gestation. Medians
(horizontal lines) are shown. Kruskall–Wallis test (p > 0.05).
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presence or absence of chorioamnionitis, the test used was
Kruskal–Wallis. A p value <0.05 was considered to be statistically
signiﬁcant.
3. Results
In relation to demographic data of the study population, no
statistically signiﬁcant differences concerning median maternal
age [25 (14–34) vs. 19 (14–44); p > 0.05] and gestational age at
delivery [34w (26w–36w6d) vs. 33w2d (28w–36w3d); p > 0.05]
were observed between the patients without and with chorioam-
nionitis, respectively. The results were stratiﬁed in two subgroups:
less than 32 weeks’ gestation and between 32 and 36 weeks. In this
analysis, no difference was veriﬁed in relation to maternal and
gestational age at delivery and other demographic and obstetric
characteristics (Table 1).
Relative quantiﬁcation of HBD1, HBD3, and HBD4 mRNA in
chorioamniotic membranes included in the study is presented in
Fig. 1. Observation determined that no statistically signiﬁcant
difference occurred in the expression of evaluated defensins
between the groups without (HBD1: 0.7-fold, HBD3: 0.9-fold,
HBD4: 0.3-fold) or with chorioamnionitis (HBD1: 1.1-fold, HBD3:
0.9-fold, HBD4: 0.4-fold; p > 0.05). The same results were veriﬁed
in gestational age stratiﬁed groups (Fig. 2). HBD4 mRNA was
undetectable in 8 (34.8%) chorioamniotic membranes samples
from study group and in 10 (33.3%) from control group.
Regarding the pregnancy complications that resulted in
preterm delivery (PPROM or PTL with intact membranes), the
relative amounts of HBD1, HBD3, and HBD4 were not signiﬁcantly
different, independent of the presence of chorioamnionitis (Fig. 3).
Among patients with histologic chorioamnionitis, patients with
PPROM (HBD1: 2.7-fold, HBD3: 0.3-fold, HBD4: 0.7-fold) presented
similar mRNA expression than those with PTL (HBD1: 0.7-fold,
HBD3: 1.2-fold, HBD4: 0.13-fold; p > 0.05) (Fig. 4).
4. Comment
Considering that human b defensins exhibit antimicrobial
activity against a broad spectrum of bacteria [5], we hypothesized
that the expression of b defensins would be increased in
chorioamniotic membranes complicated by chorioamnionitis,
assuming that, in the presence of infection and inﬂammatory
response, higher concentrations of these natural antimicrobialsTable 1
Clinical and demographic characteristics of the study population.
Week’s gestation Without chorioamnionitis 
<32 weeks (n = 8) 32w1d–36
Maternal age (years) 20.5 (16–20.5) 24.5 (14–2
Ethinicy
Caucasian 6 (75) 17 (94.4) 
Not caucasian 2 (25) 1 (5.6) 
Smoking habits
Yes 1 (12.5) 7 (31.8) 
No 7 (87.5) 11 (68.2) 
Gestational age at delivery (weeks, days) 28w3d (25w2d–31w6d) a 34w3d (3
Parity
1 2 (25) 9 (50) 
>1 6 (75) 9 (50) 
Prior adverse gestational outcomesa
Yes 4/6 (66.6) 8/9 (88.9)
No 2/6 (33.4) 1/9 (11.1)
Values are expressed as median (range) or number (%).
In the line, in comparison between groups, proportions followed by the same letter (a
a Preterm births, abortion or PPROM.
b Kruskall–Wallis test.
c Chi-square test.would be important at the maternal–fetal interface. Supporting
this hypothesis, Heine et al. [41] reported that levels of neutrophil
defensins increase exponentially in amniotic ﬂuid with increasing
severity of histologic chorioamnionitis. Moreover, Gankovskaia
et al. [11] reported that the presence of urogenital infection was
associated with increased expression of HBD1 by the cervical
mucosa.
In the present study, however, the relative amounts of HBD1,
HBD3, and HBD4 in membranes with chorioamnionitis were notWith chorioamnionitis p Value
w6d (n = 18) <32 weeks (n = 6) 32w1d–36w6d (n = 14)
4.5) 16.5 (14–16.5) 19 (14–19) 0.11b
5 (83.3) 11 (78.6) 0.51c
1 (16.4) 3 (21.4)
1 (16.6) 1 (6.6) 0.14c
5 (83.4) 13 (93.4)
3w–36w6d) b 30w1d (28w–31w5d) a 34w (32w2d–36w3d) b 0.001b
3 (50) 9 (64.3) 0.37c
3 (50) 5 (35.7)
 3/3 (100) 3/5 (60) 0.40c
 0 2/5 (40)
,b) did not statistically differ (p > 0.05).
Fig. 3. Relative quantiﬁcation of human beta defensin (HBD) 1, 3 and 4 mRNA in chorioamniotic membranes from pregnancies complicated by PTL or PPROM in relation to the
presence of histologic chorioamnionitis. Medians (horizontal lines) are shown. Kruskal–Wallis test (p > 0.05).
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in PPROM or PTL. Since preterm births can also be subdivided
according to gestational age [42], expression of the HBDs was
stratiﬁed in two subgroups: less than 32 weeks gestation and
between 32 and 36 full weeks gestation, and the same results were
veriﬁed, either in the absence or presence of chorioamnionitis. The
ﬁrst point to consider is the constitution of the control group: even
though there was no chorioamnionitis, it consisted of chorioam-
niotic membranes from patients in PTL or PPROM without
histological chorioamnionitis. Recently, Kim et al. [43] proposed
a new model of intra-amniotic microbial invasion that can explain
our results, based on the kinetics of this pathophysiological
process. As proposed by the authors, intra-amniotic bacterial
invasion occurs through a discrete region of the chorioamniotic
membranes, followed by intra-amniotic proliferation, and bacte-
rial invasion of membranes primarily extends from the amniotic
ﬂuid. Thus, focal histologic chorioamnionitis could be present in
the membranes from the control group (since intra-amniotic
infection is the principal cause of PTL or PPROM [44,45]), but it was
not detected in such cases. Some consideration should be given toFig. 4. Relative quantiﬁcation of human beta defensin (HBD) 1, 3 and 4 mRNA in
chorioamniotic membranes from pregnancies with histologic chorioamnionitis and
preterm premature rupture of membranes (PPROM) or preterm labor (PTL).
Kruskal–Wallis test (p > 0.05).the fact that the infection could be restricted to the amniotic ﬂuid
at the moment of the delivery of these patients and that the
presence of bacteria and their products in the amniotic ﬂuid can
activate cell-surface receptors that bind to the pathogen and
initiate a signal leading to the release of effector molecules, such as
interleukins and cytokines, and consequently, to increased HBD
expression (reviewed by Froy [46]). Thus, the present results may
have been affected by this condition. Although it was not the ideal
control, comparing HBD expression to term pregnancies would be
inappropriate, since striking differences have been reported
between term and preterm births, like cytokine bias [47],
myometrial gene expression [48] and species of infectious
organisms [49].
Besides the absence of chorioamnionitis but possible intra-
amniotic infection, another issue should be considered regarding
the control group. There is increasing evidence for a genetic
predisposition of the mother as a potential cause for preterm
delivery: preterm born mothers have a higher risk of delivering
prematurely themselves [50]. A medical history of preterm
delivery multiplies the risk of another preterm delivery [51].
Consequently, recent studies have lead to increasing speculation
that variations in the maternal immune response, mediated by
genetic variation in the inﬂammatory response, might be integrally
involved in the pathophysiology of spontaneous preterm labor and
preterm birth [52]. The issues regarding HBD genetic variations
and pregnancy have not yet been consistently explored, however,
and only a large study of clinically well-deﬁned cases would permit
the elucidation of the molecular mechanisms responsible for the
role of HBDs in PTL of different causes.
Another thing to consider is that the regulation of b defensin
synthesis is not the same in different systems and that in
chorioamniotic membranes in vivo, it is poorly understood. In
some cells, such as uterine macrophages, peripheral blood
monocytes [53] and amniotic cells in culture [54], stimulation
with inﬂammatory cytokines induces the synthesis of certain b
defensins. King et al. [55] reported that endometrial epithelial cells
increase the production of natural antimicrobial after stimulation
with IL-1b, a cytokine rapidly produced after the exposure of
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interface in preterm pregnancies [57]. In chorioamniotic mem-
branes, the expression of HBDs 1 and 3 may be inﬂuenced by
cytokines, regardless of the presence of chorioamnionitis. In
contrast, HBD4 may not be totally affected by proinﬂammatory
cytokine stimuli in chorioamniotic membranes, similar to that
already veriﬁed in amniotic cells [54], intestinal epithelia [58] and
in lung epithelial cell line [25]. This could explain the lack of HBD-4
expression in some samples in this study.
In addition to the differences in the presence and production of
b defensins in various tissue and cell types, the transcription factor
can justify the results obtained, given that the difference in the
amount of a speciﬁc mRNA between two biological samples is not
necessarily reﬂected by quantitative differences in the amount of
protein. It could also be explained by temporal differences between
mRNA synthesis and protein expression and the shorter half-life of
mRNA than protein [59]. This study only evaluated mRNA
expression of HBDs 1, 3 and 4 in chorioamniotic membranes
using a highly speciﬁc quantitative PCR method. Clearly, studies of
protein expression are needed to clarify their role, although this is
hampered by the high levels of structural homology between the
various defensin family members [8].
In conclusion, analysis of the results based on mRNA expression
revealed that chorioamniotic membranes from preterm births are
sources of b defensins and that, bearing in mind the sample size
and the methodology applied, the expression of HDB1, HBD3, and
HBD4 is not associated with the presence of histologic chor-
ioamnionitis in PPROM or PTL.
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